Compare MBIN & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MBIN | MESO |
|---|---|---|
| Founded | 1990 | 2004 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.0B |
| IPO Year | 2017 | 2005 |
| Metric | MBIN | MESO |
|---|---|---|
| Price | $52.81 | $15.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $43.67 | N/A |
| AVG Volume (30 Days) | 123.8K | ★ 182.2K |
| Earning Date | 04-28-2026 | 02-26-2026 |
| Dividend Yield | ★ 0.89% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.73 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $31.76 | $629.74 |
| Revenue Next Year | $3.73 | $30.65 |
| P/E Ratio | $19.47 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $30.37 | $13.05 |
| 52 Week High | $56.87 | $21.50 |
| Indicator | MBIN | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 47.83 | 42.83 |
| Support Level | $45.39 | $15.37 |
| Resistance Level | $54.48 | $16.06 |
| Average True Range (ATR) | 1.33 | 0.42 |
| MACD | -0.24 | -0.22 |
| Stochastic Oscillator | 32.29 | 1.74 |
Merchants Bancorp is a United States-based bank holding company operating multiple lines of business focused on FHA multi-family housing and healthcare facility financing and servicing, retail and correspondent residential mortgage banking, and traditional community banking. Its segments include Multi-family Mortgage Banking, which originates and services government-sponsored mortgages for multi-family and healthcare facilities; Mortgage Warehousing, which offers mortgage warehouse financing, commercial loans and deposit services; and the Banking segment, which generates maximum revenue and provides portfolio lending for multi-family and healthcare facility loans, residential mortgage banking, agricultural lending, SBA lending and community banking.
Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is also developing Ryoncil for additional inflammatory indications. Its rexlemestrocel-L platform is being developed for chronic low back pain associated with degenerative disc disease and chronic heart failure. The company operates as a single segment focused on its allogeneic cellular medicines platform.